Progyny, Inc. Payments to Acquire Debt Securities, Available-for-sale
Progyny, Inc. (PGNY) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-07
- Progyny, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Progyny, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Progyny, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $43.45M.
- Progyny, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $111.42M, a 852.35% increase year-over-year.
- Progyny, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $354.96M, a 108.39% increase from fiscal 2024.
- Progyny, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $170.34M, a 60.36% decline from fiscal 2023.
- Progyny, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $429.69M, a 163.08% increase from fiscal 2022.
- Progyny, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $163.33M, a 46.52% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $0.00 10-Q · filed 2026-08-07 | $43.45M derived: sum of 3 quarters · filed 2026-08-07 | $154.88M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-08 | $43.45M derived: sum of 2 quarters · filed 2026-05-08 | $154.88M derived: sum of 3 quarters · filed 2026-05-08 | $209.16M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $43.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $154.88M derived: sum of 2 quarters · filed 2026-02-27 | $209.16M derived: sum of 3 quarters · filed 2026-08-07 | $354.96M 10-K · filed 2026-02-27 |
| 2025-09-30 | $111.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $165.70M derived: sum of 2 quarters · filed 2026-08-07 | $311.51M 10-Q · filed 2025-11-07 | $311.51M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $54.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $200.09M 10-Q · filed 2026-08-07 | $200.09M derived: sum of 3 quarters · filed 2026-08-07 | $211.79M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $145.81M 10-Q · filed 2026-05-08 | $145.81M derived: sum of 2 quarters · filed 2026-05-08 | $157.51M derived: sum of 3 quarters · filed 2026-05-08 | $205.34M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $11.70M derived: sum of 2 quarters · filed 2026-02-27 | $59.53M derived: sum of 3 quarters · filed 2026-02-27 | $170.34M 10-K · filed 2026-02-27 |
| 2024-09-30 | $11.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $59.53M derived: sum of 2 quarters · filed 2025-11-07 | $170.34M 10-Q · filed 2025-11-07 | $337.07M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $47.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $158.64M 10-Q · filed 2025-08-08 | $325.37M derived: sum of 3 quarters · filed 2026-02-27 | $467.73M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $110.81M 10-Q · filed 2025-05-09 | $277.54M derived: sum of 2 quarters · filed 2026-02-27 | $419.90M derived: sum of 3 quarters · filed 2026-02-27 | $517.07M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $166.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $309.10M derived: sum of 2 quarters · filed 2026-02-27 | $406.26M derived: sum of 3 quarters · filed 2026-02-27 | $429.69M 10-K · filed 2026-02-27 |
| 2023-09-30 | $142.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $239.53M derived: sum of 2 quarters · filed 2024-11-12 | $262.96M 10-Q · filed 2024-11-12 | $301.14M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $97.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $120.60M 10-Q · filed 2024-08-07 | $158.78M derived: sum of 3 quarters · filed 2025-03-03 | $189.32M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $23.43M 10-Q · filed 2024-05-10 | $61.61M derived: sum of 2 quarters · filed 2025-03-03 | $92.16M derived: sum of 3 quarters · filed 2025-03-03 | $126.90M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $38.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $68.72M derived: sum of 2 quarters · filed 2025-03-03 | $103.47M derived: sum of 3 quarters · filed 2025-03-03 | $163.33M 10-K · filed 2025-03-03 |
| 2022-09-30 | $30.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $65.29M derived: sum of 2 quarters · filed 2023-11-08 | $125.16M 10-Q · filed 2023-11-08 | $146.15M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $34.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $94.61M 10-Q · filed 2023-08-04 | $115.61M derived: sum of 3 quarters · filed 2024-02-29 | $122.61M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $59.87M 10-Q · filed 2023-05-09 | $80.86M derived: sum of 2 quarters · filed 2024-02-29 | $87.86M derived: sum of 3 quarters · filed 2024-02-29 | $109.20M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $28.00M derived: sum of 2 quarters · filed 2024-02-29 | $49.33M derived: sum of 3 quarters · filed 2024-02-29 | $111.48M 10-K · filed 2024-02-29 |
| 2021-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $28.34M derived: sum of 2 quarters · filed 2022-11-04 | $90.48M 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $21.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $83.48M 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | $62.15M 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $103.96M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |